Model‐informed drug development (MIDD) has recently garnered much attention as a potential enabler of efficient drug development. In their recent article, Jain et al. describe barriers and opportunities to achieve the full potential of MIDD. The authors point out well‐accepted and promising new applications of MIDD in drug development and regulatory evaluation. There is arguably a greater appreciation of the benefits and promise of MIDD now more than ever. As noted by the authors, this is reflected by the inclusion of MIDD‐related performance goals in the latest congressionally reauthorized Prescription Drug User Fee Act (PDUFA) VI. Against this backdrop, the key question is how we capitalize on this unique opportunity to advance MIDD.
9 May 2012 in Journal of Pharmacokinetics and Pharmacodynamics